Olmez O F, Cubukcu E, Evrensel T, Kurt M, Avci N, Tolunay S, Bekar A, Deligonul A, Hartavi M, Alkis N, Manavoglu O
Department of Medical Oncology, Uludag University Medical School, Bursa, Turkey,
Clin Transl Oncol. 2014 Feb;16(2):173-7. doi: 10.1007/s12094-013-1059-4. Epub 2013 Jun 6.
Because the outcome of glioblastoma multiforme (GBM) remains dismal, there is an urgent need for a better molecular characterization of this malignancy. The aim of this prospective study was to investigate the prognostic impact of the expression of c-mesenchymal-epithelial transition (c-Met) a receptor tyrosine kinase implicated in expression growth, survival, motility/migration, and invasion in GMB patients managed according to the established diagnostic and therapeutic protocols.
Between May 2003 and March 2011, a total of 69 patients (33 males and 36 females; mean age: 52.2 ± 12.9 years, age range: 23-81 years) referred to our Department for the surgical removal of GBM were evaluated immunohistochemically for c-Met expression. Progression-free survival (PFS) and overall survival (OS) served as the main outcome measures.
Compared with c-Met- subjects (n = 38), c-Met+ subjects (n = 31) had both a significantly lower OS (15.3 ± 2.3 vs. 22.6 ± 2.5 months, respectively, p < 0.01) and PFS (12.3 ± 2.1 vs. 19.1 ± 2.6 months, respectively, p < 0.05). After allowance for potential confounders, multivariate Cox regression analysis identified c-Met+ as an independent predictor of both OS (hazard ratio = 1.7; 95 % confidence interval = 1.2-1.9, p < 0.01) and PFS (hazard ratio = 1.6; 95 % confidence interval = 1.1-2.3, p < 0.05).
Our findings suggest that c-Met immunohistochemical expression is an independent predictor of outcomes in patients with GBM treated by standard of care.
由于多形性胶质母细胞瘤（GBM）的治疗结果仍然不容乐观，因此迫切需要对这种恶性肿瘤进行更好的分子特征分析。这项前瞻性研究的目的是，在按照既定诊断和治疗方案进行治疗的GBM患者中，研究c-间充质-上皮转化（c-Met，一种参与表达生长、存活、运动/迁移和侵袭的受体酪氨酸激酶）表达的预后影响。
在2003年5月至2011年3月期间，共有69例（33例男性和36例女性；平均年龄：52.2±12.9岁，年龄范围：23 - 81岁）因手术切除GBM而转诊至我院的患者接受了c-Met表达的免疫组织化学评估。无进展生存期（PFS）和总生存期（OS）作为主要观察指标。
与c-Met阴性受试者（n = 38）相比，c-Met阳性受试者（n = 31）的OS（分别为15.3±2.3个月和22.6±2.5个月，p < 0.01）和PFS（分别为12.3±2.1个月和19.1±2.6个月，p < 0.05）均显著更低。在考虑潜在混杂因素后，多因素Cox回归分析确定c-Met阳性是OS（风险比 = 1.7；95%置信区间 = 1.2 - 1.9，p < 0.01）和PFS（风险比 = 1.6；95%置信区间 = 1.1 - 2.3，p < 0.05）的独立预测因素。
我们的研究结果表明，c-Met免疫组织化学表达是接受标准治疗的GBM患者预后的独立预测因素。
